Announcements Trials
Browse Landscape

Phase

Phase 2 107Phase 1/2 7Phase 1 7Phase NA 6Phase 2/3 6Phase 3 5Phase EARLY_PHASE1 2

Status

Unknown 6Not yet recruiting 3Recruiting 2Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Liver Neoplasms 1Hepatoblastoma 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × sintilimab × Clear all
NCT05250843 2023-10-13

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Third Affiliated Hospital, Sun Yat-Sen University

Phase 2/3 Unknown
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown
15 enrolled
Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT05002686 2021-08-24

Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

Ruijin Hospital

Phase 2/3 Unknown
60 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04167293 2021-03-23

ISBRT01

Sun Yat-sen University

Phase 2/3 Unknown
116 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03794440 2021-01-22

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2/3 Unknown
595 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04192682 2020-01-06

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Changzhou Cancer Hospital of Soochow University

Phase 2/3 Unknown
40 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡